● Recruiting

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

Condition: Heart Failure · Heart Failure With Reduced Ejection Fraction · Sponsor: Cytokinetics

PhasePhase 3

Planned participants1800

Who can joinAll sexes, 18 Years to 85 Years

Healthy volunteersNo

About this study

The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.

This description comes directly from the study's public registry record.

Talk to the study team

Cytokinetics MD · (650) 624-2929 · medicalaffairs@cytokinetics.com

Always discuss trial participation with your own doctor first.

Locations (196)

Advanced Cardiovascular, LLC	Alexander City, Alabama, United States	Recruiting
University of Alabama at Birmingham	Birmingham, Alabama, United States	Recruiting
Pima Heart and Vascular Clinical Research	Tucson, Arizona, United States	Withdrawn
National Heart Institute	Beverly Hills, California, United States	Recruiting
UC San Diego Health - Sulpizio Cardiovascular Center	La Jolla, California, United States	Recruiting
Nutrition Research Center (SPH)	Loma Linda, California, United States	Recruiting
Keck Medical Center of USC (outpatient clinic)	Los Angeles, California, United States	Recruiting
UCLA Medical Center Cardiovascular Clinic	Los Angeles, California, United States	Recruiting
University of California, Irvine Medical Center	Orange, California, United States	Recruiting
Sutter Institute for Medical Research (SIMR)	Sacramento, California, United States	Recruiting
UC Davis Health	Sacramento, California, United States	Recruiting
San Diego Cardiac Center	San Diego, California, United States	Recruiting

+ 184 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06736574